From Clinical Analytics Platform TriNetX Raises $40M to Speed Drug Trials:

Gadi Lachman, TriNetX CEO

Gadi Lachman, TriNetX CEO—

Courtesy photo

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
Decentralized Clinical Trials: The Call for a New Paradigm
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
PRA Health Sciences

Sponsored · Whitepaper
Bridging the Diversity Gap with Decentralized Trials
How a patient-centric, technology-driven approach can broaden access to research and reach patients regardless of geography, ethnicity, sex, or gender
PRA Health Sciences

Sponsored · Whitepaper
Navigating Challenges & Advancing Clinical Development: A Toolkit for Emerging Biotechs
How incorporating more virtual/hybrid trials and decentralized research into clinical development can better integrate healthcare into patients’ real lives and accelerate approval of new medications.
Medpace

Xconomy on Demand

We offer a number of ways to subscribe for free!